Abivax shares rise 5% to 123.40 euros after upsized stock offering

The French biotechnology company extended a 46% weekly rally, lifting its market value to roughly 10 billion euros as investors responded to fundraising plans after positive clinical-trial data.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.